Palvella Therapeutics, Inc. Cash and Restricted Cash
Palvella Therapeutics, Inc. (PVLA) had Cash and Restricted Cash of $54.26 million as of 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2022-08-04
- 2022-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $54.26M.
- 2022-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $83.74M.
- 2021-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $117.76M.
- 2021-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $125.05M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2022-06-30 | $54.26M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $83.74M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $117.76M 10-Q · filed 2022-08-04 |
| 2021-09-30 | $125.05M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $119.10M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $66.83M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $70.44M 10-Q · filed 2022-08-04 |
| 2020-09-30 | $66.89M 10-Q · filed 2021-11-02 |
| 2020-06-30 | $44.30M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $47.43M 10-Q · filed 2021-05-17 |
| 2019-12-31 | $62.26M 10-K · filed 2022-03-02 |
| 2019-09-30 | $46.07M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $54.90M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $52.09M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $74.87M 10-K · filed 2021-03-31 |
| 2018-09-30 | $89.48M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $50.58M 10-Q · filed 2019-08-09 |
| 2018-03-31 | $109.52M 10-Q · filed 2019-05-10 |
| 2017-12-31 | $37.88M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |